Kymera Therapeutics (KYMR) Stock Overview
A clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
KYMR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Kymera Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$72.41 |
| 52 Week High | US$103.00 |
| 52 Week Low | US$19.45 |
| Beta | 2.22 |
| 1 Month Change | 8.69% |
| 3 Month Change | 28.64% |
| 1 Year Change | 76.96% |
| 3 Year Change | 145.46% |
| 5 Year Change | -6.00% |
| Change since IPO | 117.71% |
Recent News & Updates
Recent updates
Kymera's KT-621 Shines: Phase 1b Data Boosts Momentum
Dec 08Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported And Analysts Are Boosting Their Estimates
Aug 14
Analysts Are Betting On Kymera Therapeutics, Inc. (NASDAQ:KYMR) With A Big Upgrade This Week
May 13Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth
May 08
Advancing STAT6 And TYK2 Clinical Programs Will Open New Therapeutic Markets
Advancing clinical programs and strategic partnerships could increase market share and positively impact future revenue and earnings.Kymera Therapeutics, Inc. (NASDAQ:KYMR) Annual Results: Here's What Analysts Are Forecasting For This Year
Mar 01Kymera Therapeutics: Plenty Of Potential, But A Long Way From The Finish Line
Feb 19Getting In Cheap On Kymera Therapeutics, Inc. (NASDAQ:KYMR) Is Unlikely
Feb 17Kymera: Protein Degradation Could Drive Dupixent-Like Value
Dec 07Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors
Oct 06Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith
Mar 21Shareholder Returns
| KYMR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.3% | -1.5% | 0.5% |
| 1Y | 77.0% | 20.9% | 16.6% |
Return vs Industry: KYMR exceeded the US Biotechs industry which returned 23.6% over the past year.
Return vs Market: KYMR exceeded the US Market which returned 14.5% over the past year.
Price Volatility
| KYMR volatility | |
|---|---|
| KYMR Average Weekly Movement | 13.5% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: KYMR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: KYMR's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 225 | Nello Mainolfi | www.kymeratx.com |
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases.
Kymera Therapeutics, Inc. Fundamentals Summary
| KYMR fundamental statistics | |
|---|---|
| Market cap | US$5.79b |
| Earnings (TTM) | -US$295.12m |
| Revenue (TTM) | US$43.74m |
Is KYMR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KYMR income statement (TTM) | |
|---|---|
| Revenue | US$43.74m |
| Cost of Revenue | US$304.55m |
| Gross Profit | -US$260.82m |
| Other Expenses | US$34.30m |
| Earnings | -US$295.12m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.69 |
| Gross Margin | -596.36% |
| Net Profit Margin | -674.80% |
| Debt/Equity Ratio | 0% |
How did KYMR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/06 16:41 |
| End of Day Share Price | 2026/01/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kymera Therapeutics, Inc. is covered by 36 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Etzer Darout | Barclays |
| Zhiqiang Shu | Berenberg |
| Tazeen Ahmad | BofA Global Research |